Superior tumor protection induced by a cellular vaccine carrying a tumor-specific T helper epitope by genetic exchange of the class II-associated invariant chain peptide
- PMID: 11103809
Superior tumor protection induced by a cellular vaccine carrying a tumor-specific T helper epitope by genetic exchange of the class II-associated invariant chain peptide
Abstract
Efficient loading of MHC class II molecules with a T helper epitope of choice can be achieved through genetic exchange of the MHC class II-associated invariant chain peptide (CLIP) sequence with a sequence encoding the helper peptide. We have now used this method to engineer a cellular vaccine that continuously expresses a tumor-specific helper epitope in a defined costimulatory context. We provide evidence (a) that this cellular vaccine induces peptide-specific helper T cells in vivo that are functional in protecting mice from challenge with a highly aggressive tumor, (b) that this vaccine can directly prime tumor-specific helper T cells in vivo, and (c) that this cellular vaccine is superior compared with similar cells loaded with synthetic T helper peptide in inducing tumor protection. In conclusion, cellular vaccines for activation of antigen-specific helper T cells can be greatly improved by the introduction of invariant chain constructs containing a T helper epitope by class II-associated invariant chain peptide exchange.
Similar articles
-
Efficient presentation of known HLA class II-restricted MAGE-A3 epitopes by dendritic cells electroporated with messenger RNA encoding an invariant chain with genetic exchange of class II-associated invariant chain peptide.Cancer Res. 2003 Sep 1;63(17):5587-94. Cancer Res. 2003. PMID: 14500399
-
Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.Eur J Immunol. 2009 Oct;39(10):2725-36. doi: 10.1002/eji.200939543. Eur J Immunol. 2009. PMID: 19637230
-
Deoxyribonucleic acid (DNA) encoding a pan-major histocompatibility complex class II peptide analogue augmented antigen-specific cellular immunity and suppressive effects on tumor growth elicited by DNA vaccine immunotherapy.Cancer Res. 2003 Nov 15;63(22):7920-5. Cancer Res. 2003. PMID: 14633722
-
Turning tumor cells in situ into T-helper cell-stimulating, MHC class II tumor epitope-presenters: immuno-curing and immuno-consolidation.Cancer Treat Rev. 2004 May;30(3):281-90. doi: 10.1016/j.ctrv.2003.08.002. Cancer Treat Rev. 2004. PMID: 15059651 Review.
-
CD4+ T-cell activation for immunotherapy of malignancies using Ii-Key/MHC class II epitope hybrid vaccines.Vaccine. 2012 Apr 16;30(18):2805-10. doi: 10.1016/j.vaccine.2012.02.031. Epub 2012 Mar 3. Vaccine. 2012. PMID: 22386748 Review.
Cited by
-
DNA vaccines encoding Ii-PADRE generates potent PADRE-specific CD4+ T-cell immune responses and enhances vaccine potency.Mol Ther. 2007 Jun;15(6):1211-9. doi: 10.1038/sj.mt.6300121. Epub 2007 Mar 13. Mol Ther. 2007. PMID: 17356542 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Research Materials